Proton Rahman

24.7k citations

314 papers · 11.0k indexed · 5 hit papers · h-index 53

Impact in

Rheumatology top 0.02%
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Osteoarthritis Treatment and Mechanisms
Immunology top 0.1%
- Psoriasis: Treatment and Pathogenesis
- Atherosclerosis and Cardiovascular Diseases

Papers in

Rheumatology 243
- Spondyloarthritis Studies and Treatments 164
- Rheumatoid Arthritis Research and Therapies 116
- Systemic Lupus Erythematosus Research 34
- Osteoarthritis Treatment and Mechanisms 28
Hematology 107
- Autoimmune and Inflammatory Disorders Research 107

Co-authors: Dafna D. Gladman Iain B. McInnes Alice B. Gottlieb Philip J. Mease Christopher T. Ritchlin Murray B. Urowitz Robert D. Inman Darren D. O’Rielly
Journals: Annals of the Rheumatic Diseases (67 papers)The Journal of Rheumatology (26 papers)Lara D. Veeken (17 papers)Arthritis Research & Therapy (9 papers)Current Rheumatology Reports (7 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Proton Rahman

299 papers receiving 10.7k citations

Hit Papers

5 papers align trajectories log scale

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial 2020 · 242 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 The Lancet
2015 New England Journal of Medicine
2015 The Lancet
2014 Annals of the Rheumatic Diseases
2013 The Lancet

Peers

Countries citing papers authored by Proton Rahman

Since Specialization

Citations

This map shows the geographic impact of Proton Rahman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Proton Rahman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Proton Rahman more than expected).

Fields of papers citing papers by Proton Rahman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Proton Rahman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Proton Rahman. The network helps show where Proton Rahman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Proton Rahman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Proton Rahman Line = papers co-authored together Proton Rahman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular Events Dermatology and Therapy ·Mark Lebwohl, Atul Deodhar, Sergio Schwartzman, Carlo Salvarani, Valeriia Kushnyr, Natalia Bello, Ellen Chrislley Mesquita Souza, Sitthinan Wiwatthanapornchai, 上官国锦, Marcus Ngantcha, Proton Rahman, Kim Papp, Joseph F. Merola, Alice B. Gottlieb, Andrew Blauvelt	2025	2
2	Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis Clinical Rheumatology ·Proton Rahman, Iain B. McInnes, Atul Deodhar, Georg Schett, Phillip J. Mease, M. Shawi, J. Daniel, Jonathan Sherlock, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Christopher T. Ritchlin, Dennis McGonagle	2024	0
3	Canadian Patients With Axial Spondyloarthritis Require Almost a Decade To Be Diagnosed Leading to Severe Functional Limitation. Results From the International Map of Axial Spondyloarthritis (IMAS) Musculoskeletal Care ·Proton Rahman, Marco Garrido‐Cumbrera, Sherry Rohekar, Anna-Luisa Volk, Elie G. Karam, A. Jovaisas, Nigil Haroon, Jeremy Beach, Artur J. de Brum‐Fernandes, Martin Cohen, Jonathan Chan, Xiaoliang Wang, H. Berthold, Robert D. Inman	2024	0
4	Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis Arthritis & Rheumatology ·Stefan Siebert, Laura C. Coates, Georg Schett, S. P. Raychaudhuri, Hua Liu, Sheng Gao, Loqmane Seridi, Soumya D. Chakravarty, M. Shawi, F. Lavie, Marco Vinicio Vásquez Bernal, V. M. Zolotareva, Alexa P. Kollmeier, Xie L. Xu, Proton Rahman, Philip J. Mease, Atul Deodhar	2024	4
5	Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study Rheumatology and Therapy ·Vinod Chandran, Louis Bessette, Carter Thorne, キイチロウコバヤシ, Proton Rahman, Dafna D. Gladman, О.В. Григоренко, M. I. Henderson, Nicole Bouchez-Decloux, Hsuan-Ting Kuo, John S. Sampalis	2024	3
6	POS1522 CHANGES IN SERUM CYTOKINES BY WEEK 24 CORRELATE WITH LONG-TERM EFFICACY OF GUSELKUMAB THROUGH 2-YEARS IN BIO-NAÏVE ADULTS WITH PSA Annals of the Rheumatic Diseases ·Stefan Siebert, Georg Schett, S. P. Raychaudhuri, Mónica Gumá, Umesh Kumar Pandey, Sheng Gao, Irina Rinkovec, M. Shawi, Proton Rahman	2023	1
7	Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies ACR Open Rheumatology ·Dennis McGonagle, Iain B. McInnes, Atul Deodhar, Georg Schett, M. Shawi, Soumya D. Chakravarty, Alexa P. Kollmeier, Xie L. Xu, Shihong Sheng, Stephen Xu, Christopher T. Ritchlin, Proton Rahman, Phillip J. Mease	2023	4
8	Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis Drug Safety ·Bruce Strober, Laura C. Coates, Mark Lebwohl, Atul Deodhar, Michel Wensing, Gan Chunfang, Alexa P. Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D. Chakravarty, Daphne Chan, M. Shawi, Ya‐Wen Yang, Isnan Hidayat, Proton Rahman	2023	31
9	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis Lara D. Veeken ·Laura C. Coates, Christopher T. Ritchlin, Laure Gossec, Philip Helliwell, Proton Rahman, Alexa P. Kollmeier, Xie L. Xu, M. Shawi, Chetan S. Karyekar, 连杰, W. Noël, Shihong Sheng, Yanli Wang, Stephen Xu, Philip J. Mease	2022	11
10	POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB Annals of the Rheumatic Diseases ·Peter Nash, Christopher T. Ritchlin, Proton Rahman, M. Shawi, Szilárd Szerényi, 建二国田, Alexa P. Kollmeier, X. L. Xu, M. Groenhuijsen, 星湖朴, Saakshi Khattri, Enrique R. Soriano, D. Mcgonagle	2022	1
11	POS1035 LOW RATES OF RADIOGRAPHIC PROGRESSION WITH 2 YEARS OF GUSELKUMAB, A SELECTIVE INHIBITOR OF THE INTERLEUKIN-23p19 SUBUNIT: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS Annals of the Rheumatic Diseases ·Philip J. Mease, A.B. Gottlieb, Iain B. McInnes, Proton Rahman, Alexa P. Kollmeier, X. L. Xu, 小野美帆, Wendy Faisury Izquierdo Calderón, M. Shawi, Soumya D. Chakravarty, Шаробова Махбуба Курбонмуродовна, D. van der Heijde	2022	1
12	Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study RMD Open ·Philip J. Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Jordan D. J. R. Fisher, Sandra Navarra, Aimee Readie, Shephard Mpofu, Eumorphia Maria Delicha, Luminita Pricop, Désirée van der Heijde	2021	26
13	Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis Arthritis & Rheumatology ·Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Syaiful Rahman, Shihong Sheng, M. Shawi, Soumya D. Chakravarty, Désirée van der Heijde, Philip J. Mease	2021	66
14	Endotypes of primary osteoarthritis identified by plasma metabolomics analysis Lara D. Veeken ·Jerabkova, Ming Liu, Hongwei Zhang, Guang Sun, Andrew Furey, Edward Randell, Proton Rahman, Guangju Zhai	2020	37
15	Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis Arthritis & Rheumatology ·Iain B. McInnes, Proton Rahman, Alice B. Gottlieb, Elizabeth C. Hsia, Alexa P. Kollmeier, Soumya D. Chakravarty, Xie L. Xu, Ramanand A. Subramanian, Prasheen Agarwal, Shihong Sheng, Syaiful Rahman, Bei Zhou, Yanli Zhuang, Désirée van der Heijde, Philip J. Mease	2020	56
16	Activation of The Phosphatidylcholine to Lysophosphatidylcholine Pathway Is Associated with Osteoarthritis Knee Cartilage Volume Loss Over Time Scientific Reports ·Guangju Zhai, Jean‐Pierre Pelletier, Ming Liu, Dawn Aitken, Edward Randell, Proton Rahman, Graeme Jones, Johanne Martel‐Pelletier	2019	35
17	Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5 Lara D. Veeken ·Désirée van der Heijde, Philip J. Mease, Robert Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Jordan D. J. R. Fisher, Sandra Navarra, Xuan Zhu, Gregory Ligozio, Aimee Readie, Shephard Mpofu, Luminita Pricop	2019	45
18	Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Data Archiving and Networked Services (DANS) ·Philip Mease, Iain B. McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan, Hanno B. Richards, Shephard Mpofu	2014	12
19	Ustekinumab Improves Arthritis-Related And Skin-Related Quality Of Life In Patients With Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized And Double Blinded Phase Iii Psummit I Trial Value in Health ·Arthur Kavanaugh, Iain B. McInnes, Alice B. Gottlieb, L. Puig, Proton Rahman, Christopher T. Ritchlin, Alwizar Alwizar, Zhang Yueping, Seiji Matsumoto, Aaron B. Mendelsohn, Archana Dahal	2013	1
20	A population‐based study of hereditary non‐polyposis colorectal cancer: evidence of pathologic and genetic heterogeneity Clinical Genetics ·A. H. Barry, Lihua Zhang, N. A. Petrov, Özlem Aslan, Julija Shtets, A Hoel, Elizabeth Dicks, Proton Rahman, Guangju Zhai, Patrick S. Parfrey	2012	8

About Proton Rahman

Proton Rahman is a scholar working on Rheumatology, Hematology, Immunology, Dermatology and Genetics, having authored 314 papers that have together received 11.0k indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (164 papers), Psoriasis: Treatment and Pathogenesis (146 papers), Rheumatoid Arthritis Research and Therapies (116 papers), Autoimmune and Inflammatory Disorders Research (107 papers), Systemic Lupus Erythematosus Research (34 papers), Osteoarthritis Treatment and Mechanisms (28 papers), Dermatology and Skin Diseases (16 papers) and Cytokine Signaling Pathways and Interactions (12 papers). The work is most often cited by research in Rheumatology (7.6k citations), Immunology (6.8k citations), Hematology (3.4k citations), Dermatology (1.1k citations) and Pathology and Forensic Medicine (588 citations). Proton Rahman has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Dafna D. Gladman, Iain B. McInnes, Alice B. Gottlieb, Philip J. Mease, Christopher T. Ritchlin, Murray B. Urowitz, Robert D. Inman, Darren D. O’Rielly, Arthur Kavanaugh and Désirée van der Heijde. Their work appears in journals such as Annals of the Rheumatic Diseases, The Journal of Rheumatology, Lara D. Veeken, Arthritis Research & Therapy and Current Rheumatology Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact